Barclays PLC Has $1.44 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Barclays PLC lifted its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 295.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 56,217 shares of the company’s stock after buying an additional 42,012 shares during the period. Barclays PLC owned about 0.12% of Enliven Therapeutics worth $1,435,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Quest Partners LLC raised its holdings in Enliven Therapeutics by 87.3% during the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after acquiring an additional 742 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Enliven Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock worth $232,000 after purchasing an additional 3,559 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Enliven Therapeutics during the 3rd quarter worth approximately $256,000. Verition Fund Management LLC bought a new stake in shares of Enliven Therapeutics during the 3rd quarter worth approximately $271,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at approximately $322,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Robert W. Baird boosted their target price on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, November 15th. HC Wainwright restated a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. Finally, BTIG Research began coverage on shares of Enliven Therapeutics in a research note on Friday, December 13th. They issued a “buy” rating and a $42.00 target price for the company. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $38.25.

Insider Transactions at Enliven Therapeutics

In related news, CEO Samuel Kintz sold 12,206 shares of the business’s stock in a transaction on Friday, October 4th. The stock was sold at an average price of $27.51, for a total value of $335,787.06. Following the completion of the sale, the chief executive officer now directly owns 1,036,523 shares in the company, valued at $28,514,747.73. The trade was a 1.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Benjamin Hohl sold 5,250 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $24.89, for a total value of $130,672.50. The disclosure for this sale can be found here. In the last 90 days, insiders sold 124,945 shares of company stock worth $3,478,624. 29.20% of the stock is owned by insiders.

Enliven Therapeutics Price Performance

ELVN stock opened at $22.37 on Friday. Enliven Therapeutics, Inc. has a one year low of $10.90 and a one year high of $30.03. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of -11.77 and a beta of 1.02. The company has a fifty day moving average price of $25.58 and a two-hundred day moving average price of $24.27.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.